EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Klinische Studie (Phase II)Open Access

Combination Targeted Therapy in Relapsed Diffuse Large B-Cell Lymphoma

Christopher Melani iD, Rahul Lakhotia, Stefania Pittaluga, James D Phelan, Da Wei Huang, George Wright, Jillian Simard, Jagan Muppidi, Craig J Thomas, Michele Ceribelli, Frances A Tosto, Yandan Yang und 24 weitere

New England Journal of Medicine · 20.06.2024 · 390 (23) · 2143-2155

DOI: 10.1056/nejmoa2401532 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift New England Journal of Medicine, erschienen am 20.06.2024. Verfasst von Christopher Melani und 35 weiteren Autor:innen. Beteiligte Einrichtung: From the Lymphoid Malignancies Branch (C. Melani, R.L., J.D.P., D.W.H., J.S., J.M., Y.Y., W.X., A.P., C. Morrison, A.T., A.M.J., M.R., L.M.S., W.H.W.…. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Antineoplastic Combined Chemotherapy Protocols, Lenalidomide, Lymphoma, Large B-Cell, Diffuse. Die Arbeit wurde bisher 85-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Intramural NIH HHS, National Cancer Institute, National Center for Advancing Translational Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsLenalidomideLymphoma, Large B-Cell, DiffusePiperidinesAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedAdenineBridged Bicyclo Compounds, HeterocyclicMolecular Targeted TherapyPrednisoneProgression-Free SurvivalPyrazolesPyrimidinesRecurrenceSulfonamides

Substanzen

AdenineAntibodies, Monoclonal, HumanizedBridged Bicyclo Compounds, HeterocyclicibrutinibLenalidomideobinutuzumabPiperidinesPrednisonePyrazolesPyrimidines

Autor:innen und Institutionen

  • From the Lymphoid Malignancies Branch (C. Melani, R.L., J.D.P., D.W.H., J.S., J.M., Y.Y., W.X., A.P., C. Morrison, A.T., A.M.J., M.R., L.M.S., W.H.W.), the Clinical Pharmacology Program (C.J.P., O.A., W.D.F.), the Molec…

ORCID-Profile: Christopher Melani, Crystal Lu, William D Figg, Mark Roschewski, Wyndham H Wilson

Förderung

  • Intramural NIH HHS
  • National Cancer Institute
  • National Center for Advancing Translational Sciences

Zitieren

APA

Melani, C., Lakhotia, R., Pittaluga, S., Phelan, J. D., Huang, D. W., Wright, G., Simard, J., Muppidi, J., Thomas, C. J., Ceribelli, M., Tosto, F. A., Yang, Y., Xu, W., Davies-Hill, T., Pack, S. D., Peer, C. J., Arisa, O., Mena, E., Lindenberg, L., …, & Wilson, W. H. (2024). Combination Targeted Therapy in Relapsed Diffuse Large B-Cell Lymphoma. New England Journal of Medicine, 390(23), 2143-2155. https://doi.org/10.1056/nejmoa2401532

Vancouver

Melani C, Lakhotia R, Pittaluga S, Phelan JD, Huang DW, Wright G, et al. Combination Targeted Therapy in Relapsed Diffuse Large B-Cell Lymphoma. New England Journal of Medicine. 2024;390(23):2143-2155. doi:10.1056/nejmoa2401532

BibTeX
@article{Melani2024,
  author = {Melani, Christopher and Lakhotia, Rahul and Pittaluga, Stefania and Phelan, James D and Huang, Da Wei and Wright, George and Simard, Jillian and Muppidi, Jagan and Thomas, Craig J and Ceribelli, Michele and Tosto, Frances A and Yang, Yandan and Xu, Weihong and Davies-Hill, Theresa and Pack, Svetlana D and Peer, Cody J and Arisa, Oluwatobi and Mena, Esther and Lindenberg, Liza and Bergvall, Ethan and Portell, Craig A and Farah, Rafic J and Lee, Seung Tae and Pradhan, Amynah and Morrison, Candis and Tadese, Atekelt and Juanitez, Anna Marie and Lu, Crystal and Jacob, Allison and Simmons, Heidi and Figg, William D and Steinberg, Seth M and Jaffe, Elaine S and Roschewski, Mark and Staudt, Louis M and Wilson, Wyndham H},
  title = {Combination Targeted Therapy in Relapsed Diffuse Large B-Cell Lymphoma},
  journal = {New England Journal of Medicine},
  year = {2024},
  volume = {390},
  number = {23},
  pages = {2143--2155},
  doi = {10.1056/nejmoa2401532}
}
Kostenlos starten →